Business Context and Reporting Period
This Form 8-K Current Report was filed by Caribou Biosciences, Inc. on November 4, 2021, with the report date reflecting events occurring on November 4, 2021, and a subsequent press release dated November 8, 2021. The filing primarily addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new executive officer.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial information disclosed relates to director compensation:
- Annual Cash Compensation: $40,000 for Board service.
- Committee Fee: $4,000 per year for service on the Nominating and Corporate Governance Committee.
- Equity Grant: A 10-year non-qualified stock option to purchase 44,000 shares of common stock, vesting in equal annual amounts over three years.
Material Changes
The following material changes were reported:
- Board Expansion: The Board of Directors increased its size from six to seven members.
- Director Appointment: Dara Richardson-Heron, M.D., was appointed as a Class III director effective November 4, 2021, and assigned to the Nominating and Corporate Governance Committee.
- Executive Appointment: Ruhi Khan was appointed as Chief Business Officer (announced via press release on November 8, 2021).
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific risks and contingencies. It confirms that there are no undisclosed arrangements or family relationships involving the new director that would require disclosure under Item 404(a) of Regulation S-K. The press release referenced in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 44,000-share stock option granted to Dr. Richardson-Heron.
- Review the full text of the November 8, 2021 press release (Exhibit 99.1) for details on Ruhi Khan's background and role as Chief Business Officer.
- Confirm the updated composition of the Board of Directors and committee assignments in subsequent filings.